4/A: Cue Biopharma CEO Receives Stock Grant
Insider Transaction (Form 4/A)
Shao-Lee Lin, Chief Executive Officer and a Director of Cue Biopharma, Inc., reported multiple transactions in common stock on June 1, 2026.
Summary
- Grant/award: acquired 90,906 Pre-Funded Warrants (Right to Buy) at $11.00 ($999,966) on June 1, 2026; holds 90,906 after (Indirect).
- Grant/award: acquired 45,453 Common Stock Warrants (Right to Buy) on June 1, 2026; holds 45,453 after (Indirect).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Shao-Lee Lin — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-06-01 | Grant/award | Pre-Funded Warrants (Right to Buy) | 90,906 | $11 | $1000.0K | 90,906 |
| 2026-06-01 | Grant/award | Common Stock Warrants (Right to Buy) | 45,453 | — | — | 45,453 |
Key Dates
| Date | Description |
|---|---|
| 2026-06-01 | Grant/award (90,906 shares) |
| 2026-06-01 | Grant/award (45,453 shares) |
Keywords
insider transaction, Form 4/A, CUE, Cue Biopharma, Inc., neutral, Shao-Lee Lin
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.